Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
暂无分享，去创建一个
E. Leray | S. Vukusic | E. Thouvenot | P. Cabre | G. Edan | D. Laplaud | B. Stankoff | J. Camdessanché | G. Defer | M. Debouverie | O. Gout | J. Pelletier | P. Clavelou | P. Labauge | J. de Seze | J. Ciron | E. Maillart | H. Zéphir | A. Ruet | B. Bourre | S. Wiertlewski | C. Lebrun-Frénay | E. Berger | J. Neau | R. Casey | O. Casez | A. Montcuquet | A. Maurousset | K. Hankiewicz | C. Pottier | F. Rollot | Thibault Moreau | Justine Couturier | Haifa Ben Nasr | J. Camdessanche